Hematopoietic Stem Cell Selection via MDR1 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting genetically modified hematopoietic stem cells in gene therapy face challenges such as incomplete gene transfer, safety concerns due to insertional mutagenesis, and loss of engraftment potential, particularly with the use of puromycin selection which is not effective for human hematopoietic stem cells.
Innovation Solution
A method involving the co-delivery of a polynucleotide of interest and a positive selection marker, such as puromycin N-acetyl transferase, along with a multidrug resistance 1 (MDR1) inhibitor, to selectively isolate genetically modified hematopoietic stem cells using puromycin, thereby increasing the proportion of modified cells while minimizing vector copies per cell and maintaining cell viability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If puromycin selection is used to select genetically modified hematopoietic stem cells, then unmodified cells are eliminated, but human hematopoietic stem cells cannot be effectively selected due to MDR1 expression
Solution Approach 1:
The patent introduces an MDR1 inhibitor as an intermediary substance that blocks the MDR1 efflux pump, preventing puromycin from being pumped out of the cells. This allows puromycin to accumulate inside the cells and effectively kill unmodified cells, while modified cells expressing the puromycin resistance gene survive. The inhibitor acts as a mediator that enables the selection process to work despite the presence of MDR1 expression.
Solution Approach 2:
The patent changes the chemical environment by adding an MDR1 inhibitor to the selection medium, which alters the intracellular concentration of puromycin. This parameter change (puromycin concentration inside cells) overcomes the resistance mechanism and enables effective selection of genetically modified cells.
2Productivity
If the number of vector particles is increased to improve gene transfer efficiency, then more cells are modified, but the risk of insertional mutagenesis increases
Solution Approach 1:
The patent implements a feedback mechanism where puromycin resistance serves as a selectable marker that provides immediate feedback on successful gene transfer. Only cells that have successfully integrated the vector and express the resistance gene survive puromycin selection. This feedback system allows for efficient selection of modified cells without requiring excessive vector particles, thereby reducing insertional mutagenesis risk while maintaining high modification efficiency.
3Measurement precision
If in vitro selection methods using fluorescent proteins or magnetic separation are used, then genetically modified cells can be isolated, but cell viability and engraftment potential are significantly reduced
Solution Approach 1:
The patent replaces mechanical separation methods (magnetic separation, fluorescent-activated cell sorting) with a biochemical selection method using puromycin resistance. Instead of physically manipulating and sorting cells based on surface markers or fluorescent proteins, the method uses a chemical selection pressure where only genetically modified cells expressing the resistance gene can survive. This substitution eliminates the need for lengthy and traumatic physical manipulations, preserving cell viability and engraftment potential while achieving precise isolation of modified cells.
4Ease of operation
If in vivo selection using cytotoxic drugs is used to select genetically modified cells, then selection can be performed after transplantation, but hematological toxicity and myelosuppression occur
Solution Approach 1:
The patent performs the selection action preliminarily, before transplantation into the patient. Genetically modified hematopoietic stem cells are selected in vitro using puromycin and MDR1 inhibitor before being transplanted. This preliminary selection eliminates the need for post-transplantation cytotoxic drug treatment, avoiding hematological toxicity and myelosuppression while still achieving effective selection of modified cells. The selection is completed in advance, ensuring only viable modified cells are transplanted.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively selects and preserves genetically modified hematopoietic stem cells with minimal loss of in vivo activity, enhancing the efficacy and safety of gene transfer by eliminating unmodified cells and maintaining the engraftment potential of selected cells.
Implementation Method 1
co-delivery of a polynucleotide of interest and a positive selection marker, such as puromycin N-acetyl transferase
Implementation Method 2
contacting the population of hematopoietic cells obtained in a) with an agent for selecting the marker in a) and with a multidrug resistance 1 (MDR1) inhibitor
Data Source
Figure 1
Figure 2~2d
Figure 3~4d
AI summary
The present invention relates to a method of selecting genetically modified hematopoietic stem cells using the combination of a positive selection marker and a MDR inhibitor.